Clinical Trial

The Efficacy of Carbitocin in Reduction of Blood Loss During Myomectomy

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The uterine fibroids are the most common benign tumors found in the female reproductive system. Uterine fibroids commonly cause heavy menstrual periods. The prevalence of uterine fibroids is significantly affecting up to 70-80% of women by the age of 50, with an inconsistent impact on women of African origin. Carbitocin is a synthetic analogue of oxytocin which has a longer half-life than oxytocin. A Cochrane review and meta-analysis studies found that carbitocin reduced the use of additional uterotonics and transfusion. However, few of these studies was done during myomectomy.
Trial Details
NCT Number NCT07721623
Lead Sponsor Alex Ekwueme Federal University Teaching Hospital
Conditions Blood Loss, Surgical
Enrollment 900 participants
Start Date 2026-08-15
Primary Completion 2028-08-14 (estimated)
Study Completion 2028-08-14 (estimated)
Updated on ClinicalTrials.gov 2026-07-23